The goal of re-programming the host immune system to target malignancy with durable anti-tumour clinical responses has been speculated for decades. In the last decade such speculation has been transformed into reality with unprecedented and durable responses to immune checkpoint inhibitors seen in solid tumours. This mini-review considers the mechanism of action of immune modulating agents and the potential for combination with radiotherapy in the treatment of non-small cell lung cancer.
|Number of pages||6|
|Journal||Clinical oncology (Royal College of Radiologists (Great Britain))|
|Early online date||09 Aug 2016|
|Publication status||Published - Nov 2016|